Table 1.
Patients Characteristics
| Patient Characteristics and Treatment | 2-Weekly (n = 152) | 4-Weekly (n = 53) | p Value |
|---|---|---|---|
| Age, y | 66 ± 8 | 68 ± 7 | 0.051 |
| Sex | 0.34 | ||
| Male | 89 (58.6) | 27 (50.9) | |
| Female | 63 (41.4) | 26 (49.1) | |
| Smoking history | 0.91 | ||
| Current | 61 (40.1) | 23 (43.4) | |
| Past | 77 (50.7%) | 25 (47.2) | |
| Never | 14 (9.2) | 5 (9.4) | |
| Living area | 0.27 | ||
| Urban | 117 (77.5) | 44 (84.6) | |
| Rural | 34 (22.5) | 8 (15.4) | |
| ECOG PS for durvalumab | 0.13 | ||
| 0 | 26 (17.1) | 9 (17.0) | |
| 1 | 97 (63.8) | 31 (58.5) | |
| 2 | 19 (12.5) | 4 (7.5) | |
| Unknown | 10 (6.6) | 9 (17.0) | |
| Histologic type | 0.90 | ||
| Squamous | 52 (34.2) | 17 (32.1) | |
| Nonsquamous | 91 (59.9) | 32 (60.4) | |
| Other | 9 (5.9) | 4 (7.5) | |
| Stage | 0.051 | ||
| IIBa | 0 (0.0) | 3 (5.7) | |
| IIIA | 84 (55.3) | 27 (50.9) | |
| IIIB | 57 (37.5) | 19 (35.8) | |
| IIIC | 10 (6.6) | 3 (5.7) | |
| IVAb | 1 (0.7) | 1 (1.9) | |
| PD-L1 TPS | 0.88 | ||
| <1% | 20 (13.2) | 6 (11.3) | |
| 1%–49% | 17 (11.2) | 8 (15.1) | |
| ≥50% | 41 (27.0) | 13 (24.5) | |
| Unknown | 74 (48.7) | 26 (49.1) | |
| Chemotherapy | |||
| Platinum type | 0.20 | ||
| Cisplatin | 64 (42.1) | 17 (32.1) | |
| Carboplatin | 88 (57.9) | 36 (67.9) | |
| ≥2 cycles | 136 (90.7) | 50 (94.3) | 0.41 |
| Radiation | |||
| Dose, Gy | 60 ± 2 | 60 ± 2 | 0.91 |
| Dose ≥60 Gy | 145 (95.4) | 50 (96.2) | 0.82 |
| Radiation completion to durvalumab start, d | 40 (13–128) | 43 (13–92) | 0.64 |
| ≤42 d | 86 (56.6) | 26 (49.1) | 0.34 |
| Durvalumab median number of cycles | |||
| 2-weekly | 17 (1–26) | 2 (0–12) | < 0.001 |
| 4-weekly | 0 (0–6) | 7 (1–13) | < 0.001 |
| Durvalumab median cumulative dose, mg/kg | 180 (10–270) | 180 (20–270) | 0.91 |
| Durvalumab regimen crossover | 11 (7.2) | 28 (52.8) | < 0.0001 |
| Durvalumab treatment durationc, mo | 9.1 (0.0–15.0) | 8.8 (0.0–14.8) | 0.26 |
| Durvalumab | 0.068 | ||
| Ongoing | 5 (3.3) | 7 (13.2) | |
| Completed | 62 (40.8) | 18 (34.0) | |
| Stopped | 82 (53.9) | 27 (50.9) | |
| Unknown | 3 (2.0) | 1 (1.9) | |
| Reason for stopping durvalumab | 0.68 | ||
| Progression | 35 (42.7) | 9 (33.3) | |
| Toxicity | 33 (40.2) | 13 (48.1) | |
| Other | 14 (17.1) | 5 (18.5) | |
| Disease Progression | 73 (48.0) | 18 (34.0) | 0.076 |
| Locoregional | 25 (16.4) | 9 (17.0) | 0.22 |
| Metastatic | 48 (31.6) | 9 (17.0) |
Note: Data are presented as mean (±SD), median (range), and n (%).
ECOG, Eastern Cooperative Oncology Group; PD-L1, programmed death-ligand 1; PS, performance status; TPS, tumor proportion score.
a
Unresectable or incomplete resection.
b
Single, resected extrathoracic metastasis (n = 1) and N3 upstaged to M1a.
c
In patients who have completed or stopped treatment (n = 189).